Sunday, April 17, 2016 5:53:30 PM
Thorne Research Announces Clinical Study to Assess Nicotinamide Riboside on Brain NAD+ in College Football Players
- Mayo Clinic, University of Minnesota, and ChromaDex to Collaborate on Study -
IRVINE, Calif., April 13, 2016 (GLOBE NEWSWIRE) -- Thorne Research and ChromaDex Corp. (OTCQX:CDXC) announced today a research endeavor with Mayo Clinic and the University of Minnesota Clinical and Translational Science Institute, regarding a planned clinical study to assess the effect of Nicotinamide Riboside (NR) on brain NAD+ in college football players.
The randomized, placebo controlled, double-blind study will enroll healthy male collegiate football linemen, not having a history of more than 3 concussions. Participants will take either 750 mg per day of Nicotinamide Riboside (NR) or placebo for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and real time measurement of brain NAD, using 31P MRS.
The primary outcome of the study is to measure the change in brain NAD+ levels over 3 months. The study is expected to begin in May 2016 with final data collected by March 2017.
The study will utilize advanced 7 Tesla in vivo 31P Magnetic Resonance Spectroscopy (MRS) for noninvasive measurement of brain NAD+ concentrations, NAD+/NADH ratio, and ATP, using a method pioneered by Xiao-Hong Zhu, Ph.D., Associate Professor the University of Minnesota Center for Magnetic Resonance Research.
The principal investigators of the study are Dr. Zhu and Brent A Bauer, MD, Director of the Well Living Lab and Director of the Complementary and Integrative Medicine Program at Mayo Clinic in Rochester, Minnesota.
Paul Jacobson, the CEO of Thorne Research, stated, “We now have data showing that nicotinamide riboside raises NAD+ in the blood and in the brains of animals. We have further evidence that NR raises NAD+ in white blood cells and in plasma in humans. This will be the first trial to examine whether NR raises NAD+ in the brains of humans. Since concussion activates the DNA repair enzyme PARP-1 (which consumes and lowers NAD in the brain), the possibility that NR might raise brain NAD+ levels opens an exciting new frontier in how we might be able to manage football-related concussion and other forms of traumatic brain injury in the near future.”
Frank Jaksch Jr., founder and CEO of ChromaDex, commented “We are honored to collaborate with Dr. Zhu and Dr. Bauer and their respective research teams, as well as Thorne Research on this clinical trial. The human study is designed to provide a better understanding on how NR may affect brain NAD+ levels in athletes who participate in football and other contact sports.”
Thorne Research introduced NiaCel® in 2014, which features ChromaDex’s patented ingredient NIAGEN®, the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk.
ChromaDex, through more than 50 collaborations with researchers around the world, is in the forefront of research showing that the use of NR helps preserve or restore mitochondrial function and may be beneficial in treating and/or preventing disease.
Recent CDXC News
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) • Business Wire • 06/13/2024 12:32:00 PM
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) • Business Wire • 06/07/2024 12:34:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 • Business Wire • 06/04/2024 12:32:00 PM
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • Business Wire • 05/23/2024 12:34:00 PM
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award • Business Wire • 05/22/2024 12:32:00 PM
- ChromaDex Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:05 PM
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
- Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ • PR Newswire (US) • 12/12/2023 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:12:33 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM